Reassessment of the value of lowering serum cholesterol. Questioning the wisdom of widespread intervention

Affiliations

Review

D G Labreche. Clin Pharm. 1988 Aug.

. 1988 Aug;7(8):592-603.

No abstract available

Similar articles

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
Marchioli R, Marfisi RM, Carinci F, Tognoni G. Marchioli R, et al. Arch Intern Med. 1996 Jun 10;156(11):1158-72. Arch Intern Med. 1996. PMID: 8639010 Review.
Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An opposing view.
Zweig S. Zweig S. J Fam Pract. 1988 Jun;26(6):670-5. J Fam Pract. 1988. PMID: 3132527 No abstract available.
Hypercholesterolemia. Is lipid-lowering worthwhile for older patients?
Deedwania PC. Deedwania PC. Geriatrics. 2000 May;55(5):22-8. Geriatrics. 2000. PMID: 10826262 Review.
A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Fruchart JC. Fruchart JC. Eur Heart J. 2000 Oct;21(19):1572-3. doi: 10.1053/euhj.2000.2387. Eur Heart J. 2000. PMID: 10988008 No abstract available.
[The cholesterol question. Disinformed information].
Bobbio M, Brusca A. Bobbio M, et al. G Ital Cardiol. 1991 Sep;21(9):1029-33. G Ital Cardiol. 1991. PMID: 1790828 Italian. No abstract available.